BSD Medical Debuts University of Utah’s Huntsman Cancer Institute as U.S.
Teaching Center for MicroThermX® Microwave Ablation System
SALT LAKE CITY -- July 7, 2014
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that treat cancer and benign diseases
using heat therapy, today reported that University of Utah’s Huntsman Cancer
Institute (HCI) has been established as a teaching center and Center of
Excellence in the U.S. for the MicroThermX^® Microwave Ablation System
(MicroThermX). HCI will provide training on the microwave ablation treatments
using the MicroThermX for physicians throughout the U.S. As part of the
training, physicians will be able to observe microwave ablation treatments
using the MicroThermX at HCI. HCI physicians will also provide consulting
services and serve as a resource center for information on microwave ablation
treatments using the MicroThermX.
"We are excited to have this prestigious cancer center agree to serve as a
teaching center and a Center of Excellence for the MicroThermX," said Harold
Wolcott, President of BSD Medical. "Setting up teaching centers throughout the
U.S. is part of BSD's comprehensive marketing strategy to build the network of
physicians using the MicroThermX and thus increase BSD's market share. HCI
will serve as a comprehensive resource and training center for academic and
clinical training on microwave ablation treatments using the MicroThermX for
both current and future physicians and researchers."
About Huntsman Cancer Institute
Huntsman Cancer Institute (HCI) is part of the University of Utah Health Care
system. HCI is a National Cancer Institute (NCI)-Designated Cancer Center,
which means it meets the highest standards for cancer care and research and
receives support for its scientific endeavors. HCI is also a member of the
National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the
world’s leading cancer centers. NCCN is dedicated to improving the quality and
effectiveness of care provided to patients with cancer. HCI serves thousands
of cancer patients throughout the Intermountain West every year and provides
academic and clinical training for future physicians and researchers. Patients
are referred to HCI from a broad, multistate region.HCI ensures that every
person receives excellent cancer care and is able to benefit from the latest
advances in cancer diagnosis, treatment, and prevention strategies through
participation in clinical trials.
About the MicroThermX Microwave Ablation System
The MicroThermX is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design of
the MicroThermX is the first of its kind that allows delivery of higher power
levels using a single generator.
The MicroThermX utilizes innovative synchronous phased array technology that
was developed and patented by MicroThermX BSD to provide a wide range of
uniform zones of ablation. The MicroThermX includes innovative, high-end
disposables (SynchroWave antennas) that are used in each ablation treatment
and will provide a significant ongoing revenue stream.
The soft tissue (tumor) ablation world market potential is estimated to exceed
$2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the
Company a 510(k) clearance to market the MicroThermX for ablation of soft
tissue. BSD has also received CE Marking for the MicroThermX System, which
allows BSD to market the MicroThermX in Europe. CE Marking is also recognized
in many countries outside of the EU, providing BSD the ability to market the
MicroThermX to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
microwave energy and radiofrequency (RF). BSD’s product lines include ablation
and hyperthermia treatment systems. BSD’s microwave ablation system has been
developed as a stand-alone therapy to ablate and destroy soft tissue. The
Company has developed extensive intellectual property, multiple products in
the market, and well established distribution in the United States, Europe and
Asia. BSD’s hyperthermia cancer treatment systems, which have been in use for
several years in the United States, Europe and Asia, are used to treat certain
tumors with heat (hyperthermia) while increasing the effectiveness of other
therapies such as radiation therapy. Certain of the Company’s products have
received regulatory approvals in the United States, Europe and China. For
further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts,
including statements relating to our 2014 plans, are forward-looking
statements, as defined in the Private Securities Litigation Reform Act of
1995. All forward-looking statements are subject to risks and uncertainties
detailed in the Company's filings with the Securities and Exchange Commission,
including the market demand for our MicroThermX® products and the regulatory
requirements we face. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date, except as required by law.
BSD Medical Corporation
William Barth, 801-972-5555
Press spacebar to pause and continue. Press esc to stop.